bmiMD vs Oak Longevity: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher & Publisher

Reviewed & updated August 14, 2026 · Cites primary sources (FDA, NEJM, CMS) · Not medical advice

54 providers verified independently·Independent research·How we rank →

Visit bmiMD - our pick of these two →or find your match

bmiMD beats Oak Longevity overall, scoring 8/10 vs 7.5/10. Published pricing is not a like-for-like monthly comparison: bmiMD is $289/mo month-to-month; Oak Longevity is from $119/mo. Choose bmiMD for users who want an established, large-scale platform with sam. Choose Oak Longevity for budget-conscious users who want one of the cheapest compound.

A side-by-side look at bmiMD and Oak Longevity to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Higher Rated

bmiMD

#4 of 54

8/10

Budget-friendly GLP-1 platform offering both medication types at one of the lowest price points in the market.

Visit bmiMD

Oak Longevity

#21 of 54

7.5/10

Telehealth platform offering compounded semaglutide and tirzepatide at the lower end of market pricing, alongside an oral Wegovy option, brand-name FDA-approved GLP-1s, and a longevity stack (NAD+, Glutathione, Sermorelin, Tesamorelin). Distinctive non-subscription billing, patients pay each month manually rather than auto-renew.

Visit Oak Longevity

Feature	bmiMD	Oak Longevity
Why each one	One of the largest GLP-1 telehealth platforms (80,000+ customers) with same-day physician consults and a money-back eligibility guarantee.	The no-subscription billing model, patients are not auto-charged each month and renew manually. Combined with the broadest medication mix (compounded GLP-1s + oral Wegovy + brand-name + longevity peptides), Oak occupies a unique position as a 'menu' platform vs. the typical single-product flow.
Our Score	8/10	7.5/10
Headline Price	$289/mo month-to-month	from $119/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Users who want an established, large-scale platform with same-day consults and strong promo pricing	Budget-conscious users who want one of the cheapest compounded GLP-1 entries plus a no-subscription billing model and a longevity-stack add-on (NAD+, Sermorelin)
Watch out for	Standard semaglutide pricing is $289/mo, above competitors at $99-199/mo; the TAKEOFF 3-month entry (about $99/mo first month) and annual plans from $99/mo bring the effective rate down	Brand-name pricing ($1,200-$1,500/mo) is significantly above market, NovoCare lists Wegovy pen $199/mo for the first two 0.25 mg or 0.5 mg fills through December 31, 2026, then $349/mo at standard strengths or $399/mo for Wegovy HD; oral pill from $149/mo, dose-dependent and LillyDirect has Zepbound from $299. Use Oak for its compounded tiers and buy brand-name direct
Ranking	#4	#21
Get started	Visit bmiMD	Visit Oak Longevity

Pros & Cons Compared

bmiMD

Pros

+Same-day physician consults, one of the few platforms offering telehealth appointments the same day you apply
+80,000+ customer base with a 4.3-star Trustpilot rating (600+ reviews) provides real social proof of reliability
+100% money-back guarantee if your consultation determines you don't qualify for GLP-1 treatment
+HSA/FSA accepted for all programs

Cons

−Standard semaglutide pricing is $289/mo, above competitors at $99-199/mo; the TAKEOFF 3-month entry (about $99/mo first month) and annual plans from $99/mo bring the effective rate down
−$29.99 shipping fee per order where most competitors ship free; factor it into your monthly total
−A $50 non-refundable cancellation fee applies after intake approval; decide before the consult, and cancel at least 48 hours ahead of your monthly processing date

Oak Longevity

Pros

+$119/mo for compounded semaglutide is among the lowest published entries in our provider table
+No-subscription model, patients are not auto-charged each month, choose to renew manually. Reduces unwanted recurring charges
+Compounded tirzepatide at $185/mo is competitively priced for a GLP-1+GIP dual agonist
+Broadest medication mix on the platform: compounded sema + tirz, oral Wegovy, brand Wegovy/Ozempic/Zepbound/Mounjaro, plus longevity peptides (NAD+, Glutathione, Sermorelin, Tesamorelin)
+Money-back guarantee if not approved by physician, useful safety net for borderline-eligibility patients
+Free shipping and free health coaching included in every program

Cons

−Brand-name pricing ($1,200-$1,500/mo) is significantly above market, NovoCare lists Wegovy pen $199/mo for the first two 0.25 mg or 0.5 mg fills through December 31, 2026, then $349/mo at standard strengths or $399/mo for Wegovy HD; oral pill from $149/mo, dose-dependent and LillyDirect has Zepbound from $299. Use Oak for its compounded tiers and buy brand-name direct
−No published lab panels and no specialty (obesity medicine) physicians disclosed, clinical oversight is lighter than lab-driven platforms
−The 'up to 50% cheaper than competitors' marketing claim is unverified and inconsistent, judge Oak on its posted prices, which are genuinely low, not on the slogan
−The longevity add-ons (NAD+, Sermorelin, Tesamorelin) have limited clinical evidence for weight loss specifically, if weight loss is the goal, the GLP-1 alone does the work and the stack is optional
−Newer brand without disclosed company history, founding date, or executive team on landing pages
−Three-month plans are billed upfront, start on the 1-month plan if you're testing the platform, then bundle once it fits

Our Verdict

bmiMD edges out Oak Longevity with a score of 8/10 vs 7.5/10. Published pricing is not a like-for-like monthly comparison: bmiMD is $289/mo month-to-month; Oak Longevity is from $119/mo. Choose bmiMD if you want: users who want an established, large-scale platform with same-day consults and strong promo pricing. Choose Oak Longevity if you want: budget-conscious users who want one of the cheapest compounded glp-1 entries plus a no-subscription billing model and a longevity-stack add-on (nad+, sermorelin).